ClinicalTrials.gg

Program

SPT-300

A development code. Also written as “LYT-300”.

Its studies are mostly in Depressive Disorder, Major, led by 2 companies.

Furthest: phase 2, since Jul 3, 20253 company-led studies, 2 open or runningNext primary completion: Mar 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Seaport Therapeutics22 open or runningphase 2since Jul 3, 2025Jul 3, 2025Mar 2027phase 2 · NCT07065240
PureTech10 open or runningphase 2since Oct 31, 2021Oct 31, 2021none ahead

Also a collaborator on its studies: novotech-australia-pty-limited.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 31, 2021First study: phase 2 study in Healthy VolunteersNew to PureTechPureTech · NCT05129865 · 186 enrolled · Australia
  2. Jul 3, 2025Seaport Therapeutics's first study: phase 2 study in Depressive Disorder, MajorNew to Seaport TherapeuticsSeaport Therapeutics · NCT07065240 · 360 planned · United States, Bulgaria, Czechia and more
  3. Sep 2, 2025Phase 2 study in Depressive Disorder, MajorSeaport Therapeutics · NCT07161700 · 360 planned · United States, Bulgaria, Czechia and more

Ahead

  1. Mar 2027Primary completion: phase 2 study in Depressive Disorder, MajorSeaport Therapeutics · NCT07065240
  2. May 2027Primary completion: phase 2 study in Depressive Disorder, MajorSeaport Therapeutics · NCT07161700

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07161700Depressive Disorder, Major · United States, Bulgaria, Czechia and more2By invitationSeaport TherapeuticsMay 2027360
NCT07065240Depressive Disorder, Major · United States, Bulgaria, Czechia and more2RecruitingSeaport TherapeuticsMar 2027360
NCT05129865Healthy Volunteers · Australia2CompletedPureTechOct 18, 2023186

How it is read

Names in the registry

  • “SPT-300”, 2 entries
  • “LYT-300”, 1 entry

Codes read as this program: SPT300, LYT300.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.